HHS Team Heads To England To Analyze Fluvirin Data
This article was originally published in The Pink Sheet Daily
Executive Summary
CBER Director Jesse Goodman will lead team in discussions with the U.K. regulatory agency. HHS Secretary Thompson hopes to secure a partial release of Fluvirin doses following suspension of Chiron’s license to manufacture influenza vaccine for three months.
You may also be interested in...
Chiron To Meet With U.K. Regulatory Authorities On Fluvirin Suspension
The company does not anticipate the three-month manufacturing suspension will be lifted following the Oct. 6 meeting. Chiron's projected 48 mil. doses of flu vaccine were expected to account for nearly 50% of the U.S. supply.
Chiron Issues Fourth Quarter, Full-Year Earnings Restatement
The restatement is the result of improper revenue recognition of traveler vaccines in the second quarter and later periods, Chiron says. The company also reports lower flu vaccine sales as part of the restatement.
Chiron Issues Fourth Quarter, Full-Year Earnings Restatement
The restatement is the result of improper revenue recognition of traveler vaccines in the second quarter and later periods, Chiron says. The company also reports lower flu vaccine sales as part of the restatement.